论文信息 - Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

The authors report on an open-label study of an MF59-adjuvanted vaccine against avian influenza. The findings indicate that priming subjects with H5 antigen induces a rapidly mobilized, long-lasting immune memory after the administration of low-dose, antigenically distinct vaccine.

[1] R. Bugarini,et al. Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult Volunteers , 2006, Journal of Virology.

[2] D. Cummings,et al. Strategies for mitigating an influenza pandemic , 2006, Nature.

[3] Y. Guan,et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4] Maria Zambon,et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. , 2003, Vaccine.

[5] M. Zambon,et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza , 2001, The Lancet.